Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Public ClinicalTrials.gov record NCT01103414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.
Study identification
- NCT ID
- NCT01103414
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 356 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2010 (Type not available)
- Primary completion
- Nov 2011 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Apr 28, 2015
2010 – 2011
United States locations
- U.S. sites
- 24
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Muscle Shoals | Alabama | — | — |
| Not listed | Chino | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Spring Valley | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | New Port Richley | Florida | — | — |
| Not listed | Palm Harbor | Florida | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Grand Rapids | Michigan | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Kettering | Ohio | — | — |
| Not listed | Tiffin | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Eugene | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Corpus Christi | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01103414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2015 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01103414 live on ClinicalTrials.gov.